Jump to main content
eTG Complete
Index
Search
Home
Cardiovascular
Lipid modification
Approach to drug therapy for lipid modification
Cardiovascular
Atherosclerotic cardiovascular disease risk estimation
Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease
Lipid modification
How to decide when to start lipid-modifying therapy
Measurement of lipid concentrations
Target lipid concentrations
Nondrug therapy for lipid modification
Approach to drug therapy for lipid modification
First-line lipid-modifying drug therapy
Second-line lipid-modifying drug therapy
Statins for lipid modification
Ezetimibe for lipid modification
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lipid modification
Elevated triglycerides
Familial hypercholesterolaemia
Secondary dyslipidaemia
References
Blood pressure reduction
Acute chest pain of possible cardiac origin
Acute coronary syndromes
Stable angina
Antithrombotic therapy after endovascular and cardiac interventions
Secondary prevention of atherosclerotic cardiovascular events
Peripheral artery disease
Pericarditis
Heart failure
Cardiac rehabilitation programs
Tachyarrhythmias
Bradyarrhythmias
Orthostatic hypotension
Pulmonary hypertension
Venous thromboembolism
Periprocedural management of patients with cardiovascular disease
Principles of anticoagulant therapy
Approach to drug therapy for lipid modification
First-line lipid-modifying drug therapy
Second-line lipid-modifying drug therapy
